Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15394247 | 1.00 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL15071556 | 1.00 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL15071561 | 1.00 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL12452534 | 0.86 | ALDH1A1 (0.47) | LMNAKMT2AHTTALDH1A1TSHR | |
| SCHEMBL14929037 | 0.86 | LMNA (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL18561531 | 0.86 | LMNA (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL18671857 | 0.86 | LMNA (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL38660515 | 0.76 | LGALS9 (0.48) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL19866479 | 0.76 | LGALS9 (0.49) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL12522983 | 0.75 | TRPM8 (0.42) | LMNAKMT2AMAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637475-B1 | Modified 2′ and 3′ nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | LGALS9 1017/4885LGALS1 648/4885LGALS3 292/4885 |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | LGALS9 1795/4885LGALS1 1191/4885LGALS3 820/4885 |
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | LGALS9 1017/4885LGALS1 648/4885LGALS3 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.